Profile data is unavailable for this security.
About the company
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Revenue in USD (TTM)126.33m
- Net income in USD-113.72m
- Incorporated2010
- Employees233.00
- LocationSeres Therapeutics Inc200 Sidney StCAMBRIDGE 02139-4218United StatesUSA
- Phone+1 (617) 945-9626
- Fax+1 (302) 655-5049
- Websitehttps://www.serestherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | 146.03m | -143.10m | 128.11m | 325.00 | -- | -- | -- | 0.8773 | -1.25 | -1.25 | 1.28 | -1.19 | 0.4879 | 1.36 | 3.94 | 449,332.30 | -47.81 | -53.02 | -61.78 | -65.85 | 96.62 | 97.18 | -97.99 | -125.15 | 3.32 | -10.06 | 1.81 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 380.79m | 49.27m | 128.79m | 384.00 | 2.70 | 0.2968 | 2.56 | 0.3382 | 0.7045 | 0.7045 | 5.43 | 6.40 | 0.8379 | 1.06 | 13.76 | 991,630.20 | 10.84 | -- | 12.63 | -- | 93.32 | -- | 12.94 | -- | 5.20 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 128.91m | 37.00 | -- | 1.05 | -- | 123.68 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 130.65m | 143.00 | -- | 0.4043 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 130.82m | 37.00 | 26.31 | 4.84 | 24.27 | 2.48 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Repare Therapeutics Inc | 51.13m | -93.80m | 134.98m | 179.00 | -- | 0.6364 | -- | 2.64 | -2.23 | -2.23 | 1.21 | 5.03 | 0.1655 | -- | 5.21 | 285,659.20 | -30.36 | -23.40 | -37.50 | -26.37 | -- | -- | -183.44 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.88m | 135.00m | 10.00 | -- | 1.06 | -- | 67.50 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Seres Therapeutics Inc | 126.33m | -113.72m | 137.27m | 233.00 | -- | -- | -- | 1.09 | -0.897 | -0.897 | 0.9829 | -0.3322 | 0.3572 | -- | -- | 542,167.40 | -32.15 | -41.51 | -43.48 | -54.13 | -- | -- | -90.02 | -170.14 | 1.48 | -18.38 | 1.79 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| CytoDyn Inc | 0.00 | -51.69m | 137.28m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 137.40m | 53.00 | 8.85 | 2.96 | 8.13 | 2.90 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 140.78m | 9.00 | -- | 1.29 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 143.80m | 68.00 | -- | 8.54 | -- | 14.47 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| I-Mab ADR | 3.82m | -202.67m | 145.26m | 318.00 | -- | 0.6114 | -- | 38.00 | -2.29 | -2.29 | 0.0445 | 2.94 | 0.0083 | -- | -- | -- | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -- | -- |
Data as of Apr 29 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD
32.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 19.39m | 12.84% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.75m | 4.47% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.84m | 3.87% |
| Hudson Bay Capital Management LPas of 31 Dec 2023 | 4.32m | 2.86% |
| Millennium Management LLCas of 31 Dec 2023 | 2.22m | 1.47% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.19m | 1.45% |
| BofA Securities, Inc.as of 31 Dec 2023 | 2.18m | 1.45% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.09m | 1.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.91m | 1.27% |
| Tang Capital Management LLCas of 31 Dec 2023 | 1.79m | 1.19% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
